Results 31 to 40 of about 735,101 (274)

Supplementary Table – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

, 2021
Supplementary Table 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status The reasons for dose reduction
Yoshitaka Zenke (11680101), Taiki Hakozaki (11680100), Yasuhiro Kato (523643), Shingo Kitagawa (9285861), Yusuke Okuma (394608), Shigemasa Takamizawa (11680098)   +5 more
core   +1 more source

Supplementary Figures – First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status

, 2021
Supplementary Figure 1. First-line Osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status CONSORT diagram of patient selection.
Yoshitaka Zenke (11680101), Taiki Hakozaki (11680100), Yasuhiro Kato (523643), Shingo Kitagawa (9285861), Yusuke Okuma (394608), Shigemasa Takamizawa (11680098)   +5 more
core   +1 more source

Association between mental health and academic performance among university undergraduates: The interacting role of lifestyle behaviors

International Journal of Methods in Psychiatric Research, 2023
Objectives Impaired mental health status tends to be associated with poor academic performance, but few prospective studies have examined the association between mental health and academic performance among undergraduates while considering the ...
Tianshu Chu, Xin Liu, Shigemi Takayanagi, Tomoko Matsushita, Hiro Kishimoto   +4 more
doaj   +1 more source

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

JTO Clinical and Research Reports, 2022
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance ...
Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD   +20 more
doaj   +1 more source

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin

South Asian Journal of Cancer, 2016
Objective: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin.
S B Dessai, S Chakraborty, T. V. S. Babu, S Nayanar, A Bhattacharjee, J Jones, S Balasubramanian, Vijay M Patil   +7 more
doaj   +1 more source

Sarcopenia are Associated with Poor Performance Status in Indonesian Patients with Hepatocellular Carcinoma

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2022
Background: Sarcopenia affects hepatocellular carcinoma (HCC) prognosis. Sarcopenia can be assessed by using skeletal muscle index (SMI), measured on transverse CT images at the third lumbar vertebra (L3).
Hendra Koncoro, Irsan Hasan, C Rinaldi Lesmana, Humala Prika Aditama, Thariqah Salamah, Aulia Rizka, Edy Rizal Wahyudi, Hamzah Shatri   +7 more
doaj   +1 more source

Performance Comparison of Three Data-Poor Methods With Various Types of Data on Assessing Southern Atlantic Albacore Fishery

Frontiers in Marine Science, 2022
In the world, more than 80% of the fisheries by numbers and about half of the catches have not been formally analyzed and evaluated due to limited data. It has led to the fast growth of data-poor evaluation methods.
Baochao Liao, Youwei Xu, Youwei Xu, Mingshuai Sun, Mingshuai Sun, Kui Zhang, Kui Zhang, Qun Liu   +7 more
doaj   +1 more source

Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients

Cancer Research, Statistics, and Treatment, 2019
Background: Outcomes based on liquid biopsy in poor performance, older, biopsy-ineligible advanced non-small cell lung cancer (NSCLC) patients are unknown.
Avinash Pandey, Sarjana Dutt, Anjana Singh, Amit Kumar, Shivkant Singh   +4 more
doaj   +1 more source

Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. [PDF]

Cancers (Basel)
Background: Ipilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium (IMDC) intermediate ...
Shani Shrem N, Beltran-Bless AA, Ghosh S, Tajzler C, Wood LA, Kollmannsberger C, Basappa NS, Graham J, Fallah-Rad N, Heng DYC, Soulières D, Lalani AA, Breau RH, Finelli A, Tanguay S, Bhindi B, Bjarnason G, Pouliot F, Canil C.   +18 more
europepmc   +3 more sources

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Frontiers in Oncology, 2018
IntroductionThe phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG ...
Ajeet Gajra, Nagla Abdel Karim, Deborah A. Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Haythem Y. Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, David R. Spigel   +11 more
doaj   +1 more source